Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH)
- PMID: 21095413
- DOI: 10.1016/j.mcna.2010.08.013
Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH)
Abstract
Male lower urinary tract symptoms, benign prostatic hyperplasia, enlargement of the prostate, and bladder outlet obstruction are common among aging men and will increase in socioeconomic and medical importance at a time of increased life expectancy and aging of the baby boomer generation. This article reviews the epidemiology, management, and therapeutic options for these conditions. In patients bothered by moderate to severe symptoms, providers can make educated and differential choices between several classes of drugs, alone or in combination, to treat effectively and improve the symptoms in most men. Despite the efficacy of medical therapy, there will be patients who require referral to a urologist either early, to rule out prostate cancer and other conditions, or later, after initial medical therapy and lifestyle management has failed. Perhaps as many as 30% of patients fail to achieve sufficient symptom improvement with medication, lifestyle adjustment, and fluid management, and may require more invasive or surgical treatment options.
Copyright © 2011 Elsevier Inc. All rights reserved.
Similar articles
-
[Initial assessment, follow-up and treatment of lower urinary tract symptoms related to benign prostatic hyperplasia: guidelines of the LUTS committee of the French Urological Association].Prog Urol. 2012 Dec;22(16):977-88. doi: 10.1016/j.purol.2012.10.001. Epub 2012 Nov 6. Prog Urol. 2012. PMID: 23178093 French.
-
Benign prostatic hyperplasia - progress in pathophysiology and management.Pol Merkur Lekarski. 2015 Nov;39(233):263-70. Pol Merkur Lekarski. 2015. PMID: 26637089
-
The role of combination medical therapy in benign prostatic hyperplasia.Int J Impot Res. 2008 Dec;20 Suppl 3:S33-43. doi: 10.1038/ijir.2008.51. Int J Impot Res. 2008. PMID: 19002123 Review.
-
Benign Prostatic Hyperplasia.Prim Care. 2019 Jun;46(2):223-232. doi: 10.1016/j.pop.2019.02.003. Epub 2019 Apr 1. Prim Care. 2019. PMID: 31030823 Review.
-
Current medical treatment of lower urinary tract symptoms/BPH: do we have a standard?Curr Opin Urol. 2014 Jan;24(1):21-8. doi: 10.1097/MOU.0000000000000007. Curr Opin Urol. 2014. PMID: 24231531 Review.
Cited by
-
Determination of miRNA expression profile in patients with prostate cancer and benign prostate hyperplasia.Turk J Med Sci. 2022 Jun;52(3):788-795. doi: 10.55730/1300-0144.5374. Epub 2022 Jun 16. Turk J Med Sci. 2022. PMID: 36326314 Free PMC article.
-
Musulju improves benign prostatic hyperplasia by regulating inflammatory and apoptotic proteins.Mol Med Rep. 2016 Nov;14(5):4692-4698. doi: 10.3892/mmr.2016.5839. Epub 2016 Oct 12. Mol Med Rep. 2016. PMID: 27748836 Free PMC article.
-
TGFβ2 mediates oxidative stress-induced epithelial-to-mesenchymal transition of bladder smooth muscle.In Vitro Cell Dev Biol Anim. 2024 Aug;60(7):793-804. doi: 10.1007/s11626-024-00864-9. Epub 2024 Feb 26. In Vitro Cell Dev Biol Anim. 2024. PMID: 38409639 Free PMC article.
-
Increased susceptibility of estrogen-induced bladder outlet obstruction in a novel mouse model.Lab Invest. 2015 May;95(5):546-60. doi: 10.1038/labinvest.2015.30. Epub 2015 Feb 23. Lab Invest. 2015. PMID: 25706094
-
Combination of Lycopene and Curcumin Synergistically Alleviates Testosterone-Propionate-Induced Benign Prostatic Hyperplasia in Sprague Dawley Rats via Modulating Inflammation and Proliferation.Molecules. 2023 Jun 21;28(13):4900. doi: 10.3390/molecules28134900. Molecules. 2023. PMID: 37446563 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical